The aim of this study was to examine the potential relationship between IGF-1 levels and the risk of new-onset NAFLD in patients with pituitary neuroendocrine tumors (PitNET). This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatotic liver disease.